Both studies looked at the BrainPath Approach, a proprietary intervention based on Myriad tissue removal technology and NICO BrainPath access technology developed by manufacturer NICO.
“The inertia has been against aggressive surgical intervention for this disease, but there has also been a constant pressure for progress for this group of patients who have had very bleak recovery or survival odds,” Mark Bain, MD, a Cleveland Clinic neurosurgeon, said in a statement. “There has been a need to have data supporting this approach in order to take the big jump for changing how quickly we address hemorrhagic stroke and how we approach it. This is the first step.”
Of nearly 50 patients treated using this approach between the two studies, only one died. Patients diagnosed with hemorrhagic stroke generally have more than a 50 percent mortality rate, according to the researchers. NICO plans to begin a trial this year with two Atlanta-based stroke centers that will evaluate the clinical effectiveness of early surgical intervention using its proprietary method for patients who experience ischemic hemorrhagic stroke.
More articles on quality:
Statin drugs significantly reduce infection risk in stroke patients, researchers report
Researchers say new diabetes drug prevents heart attack, stroke
Brain scans predict post-treatment brain bleeding after stroke
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
